These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 22382685)

  • 1. The transmembrane adaptor protein, linker for activation of T cells (LAT), regulates RANKL-induced osteoclast differentiation.
    Kim K; Kim JH; Moon JB; Lee J; Kwak HB; Park YW; Kim N
    Mol Cells; 2012 Apr; 33(4):401-6. PubMed ID: 22382685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted inhibition of phospholipase C γ2 adaptor function blocks osteoclastogenesis and protects from pathological osteolysis.
    Decker C; Hesker P; Zhang K; Faccio R
    J Biol Chem; 2013 Nov; 288(47):33634-33641. PubMed ID: 24081142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pim-1 regulates RANKL-induced osteoclastogenesis via NF-κB activation and NFATc1 induction.
    Kim K; Kim JH; Youn BU; Jin HM; Kim N
    J Immunol; 2010 Dec; 185(12):7460-6. PubMed ID: 21068407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early estrogen-induced gene 1, a novel RANK signaling component, is essential for osteoclastogenesis.
    Choi HK; Kang HR; Jung E; Kim TE; Lin JJ; Lee SY
    Cell Res; 2013 Apr; 23(4):524-36. PubMed ID: 23478294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The inhibitory effect and the molecular mechanism of glabridin on RANKL-induced osteoclastogenesis in RAW264.7 cells.
    Kim HS; Suh KS; Sul D; Kim BJ; Lee SK; Jung WW
    Int J Mol Med; 2012 Feb; 29(2):169-77. PubMed ID: 22038020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
    Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
    Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-10 inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos and c-Jun in RAW264.7 cells and mouse bone marrow cells.
    Mohamed SG; Sugiyama E; Shinoda K; Taki H; Hounoki H; Abdel-Aziz HO; Maruyama M; Kobayashi M; Ogawa H; Miyahara T
    Bone; 2007 Oct; 41(4):592-602. PubMed ID: 17627913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SLAT negatively regulates RANKL-induced osteoclast differentiation.
    Youn BU; Kim K; Kim JH; Lee J; Moon JB; Kim I; Park YW; Kim N
    Mol Cells; 2013 Sep; 36(3):252-7. PubMed ID: 23996528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parthenolide inhibits osteoclast differentiation and bone resorbing activity by down-regulation of NFATc1 induction and c-Fos stability, during RANKL-mediated osteoclastogenesis.
    Kim JY; Cheon YH; Yoon KH; Lee MS; Oh J
    BMB Rep; 2014 Aug; 47(8):451-6. PubMed ID: 24314143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
    Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
    Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trichostatin A inhibits osteoclastogenesis and bone resorption by suppressing the induction of c-Fos by RANKL.
    Kim HN; Ha H; Lee JH; Jung K; Yang D; Woo KM; Lee ZH
    Eur J Pharmacol; 2009 Nov; 623(1-3):22-9. PubMed ID: 19766111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MafB negatively regulates RANKL-mediated osteoclast differentiation.
    Kim K; Kim JH; Lee J; Jin HM; Kook H; Kim KK; Lee SY; Kim N
    Blood; 2007 Apr; 109(8):3253-9. PubMed ID: 17158225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acteoside suppresses RANKL-mediated osteoclastogenesis by inhibiting c-Fos induction and NF-κB pathway and attenuating ROS production.
    Lee SY; Lee KS; Yi SH; Kook SH; Lee JC
    PLoS One; 2013; 8(12):e80873. PubMed ID: 24324641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SH3BP2 cherubism mutation potentiates TNF-α-induced osteoclastogenesis via NFATc1 and TNF-α-mediated inflammatory bone loss.
    Mukai T; Ishida S; Ishikawa R; Yoshitaka T; Kittaka M; Gallant R; Lin YL; Rottapel R; Brotto M; Reichenberger EJ; Ueki Y
    J Bone Miner Res; 2014 Dec; 29(12):2618-35. PubMed ID: 24916406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The paired-box homeodomain transcription factor Pax6 binds to the upstream region of the TRAP gene promoter and suppresses receptor activator of NF-κB ligand (RANKL)-induced osteoclast differentiation.
    Kogawa M; Hisatake K; Atkins GJ; Findlay DM; Enoki Y; Sato T; Gray PC; Kanesaki-Yatsuka Y; Anderson PH; Wada S; Kato N; Fukuda A; Katayama S; Tsujimoto M; Yoda T; Suda T; Okazaki Y; Matsumoto M
    J Biol Chem; 2013 Oct; 288(43):31299-312. PubMed ID: 23990468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Akt induces osteoclast differentiation through regulating the GSK3β/NFATc1 signaling cascade.
    Moon JB; Kim JH; Kim K; Youn BU; Ko A; Lee SY; Kim N
    J Immunol; 2012 Jan; 188(1):163-9. PubMed ID: 22131333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of ANTXR1 in the regulation of RANKL-induced osteoclast differentiation and function.
    Baek JM; Kwak SC; Yoon KH; Kim JY; Lee MS
    Biochem Biophys Res Commun; 2019 Mar; 510(2):296-302. PubMed ID: 30686531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of LRRc17 as a negative regulator of receptor activator of NF-kappaB ligand (RANKL)-induced osteoclast differentiation.
    Kim T; Kim K; Lee SH; So HS; Lee J; Kim N; Choi Y
    J Biol Chem; 2009 May; 284(22):15308-16. PubMed ID: 19336404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms involved in enhancement of osteoclast formation by activin-A.
    Kajita T; Ariyoshi W; Okinaga T; Mitsugi S; Tominaga K; Nishihara T
    J Cell Biochem; 2018 Aug; 119(8):6974-6985. PubMed ID: 29737562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angelica sinensis extract inhibits RANKL-mediated osteoclastogenesis by down-regulated the expression of NFATc1 in mouse bone marrow cells.
    Kong L; Zhao Q; Wang X; Zhu J; Hao D; Yang C
    BMC Complement Altern Med; 2014 Dec; 14():481. PubMed ID: 25496242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.